United Therapeutics (UTHR) Share-based Compensation (2009 - 2026)

United Therapeutics has disclosed Share-based Compensation across 18 years of filings, most recently posting $33.9 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $33.9 million, up 6.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $149.8 million (changed 0.27% YoY), and the FY2025 annual result was $147.7 million, up 2.57% from the prior year.
• Share-based Compensation came in at $33.9 million for Q1 2026 at United Therapeutics, down from $39.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $65.5 million in Q2 2022 to a low of -$21.1 million in Q1 2022.
• The 5-year median for Share-based Compensation is $31.8 million (2025), against an average of $27.7 million.
• Across the five-year window, Share-based Compensation slumped 152.62% in 2022 and soared 979.17% in 2023, its largest moves.
• United Therapeutics' Share-based Compensation stood at $64.8 million in 2022, then tumbled by 74.38% to $16.6 million in 2023, then jumped by 62.65% to $27.0 million in 2024, then soared by 44.44% to $39.0 million in 2025, then retreated by 13.08% to $33.9 million in 2026.
• The last three Share-based Compensation figures came in at $33.9 million (Q1 2026), $39.0 million (Q4 2025), and $39.1 million (Q3 2025), per Business Quant data.